The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

Patients who did not complete a distress screener were also less likely to receive autologous stem cell transplants.

Combining BET inhibitors and PARP inhibitors might help patients resistant to chemotherapy, the study suggests.

Researchers of a Swedish study advise physicians to consult with their patients about these risks and take extra precautions, ...

Although the gap between low and high value has been established in many areas, insurance design has yet to adapt, according ...

The PROMPT trials evaluate the influence of electronic health alerts for informing appropriate, evidence-based therapies to patients with cardiovascular conditions.

The extension of the emergency declaration, originally set to expire on March 21, continues to allocate funding to addressing ...

Regulating hemoglobin levels could help reduce inflammation and improve rheumatoid arthritis management. Hemoglobin (Hb) is ...

Clinical characteristics were associated with different survival outcomes in patients treated with immune checkpoint ...